In vitro analysis of PARP inhibitor nanoformulations
Paige Baldwin,1 Shifalika Tangutoori,1,2 Srinivas Sridhar1,2 1Nanomedicine Science and Technology Center, Northeastern University, Boston, MA, USA; 2Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA, USA Abstract: PARP-l is a DNA repair protein that plays a role in a numbe...
Guardado en:
Autores principales: | Baldwin P, Tangutoori S, Sridhar S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5f6d8cd0e01943c2a743e1b6e2b71fde |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment
por: Baldwin P, et al.
Publicado: (2018) -
Optimizing the Schedule of PARP Inhibitors in Combination with <sup>177</sup>Lu-DOTATATE: A Dosimetry Rationale
por: Andreas Hallqvist, et al.
Publicado: (2021) -
PARP Inhibitors and Haematological Malignancies—Friend or Foe?
por: Kathryn A. Skelding, et al.
Publicado: (2021) -
Olaparib nanoparticles potentiated radiosensitization effects on lung cancer
por: Wu M, et al.
Publicado: (2018) -
Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Giacomo Barchiesi, et al.
Publicado: (2021)